Table 3 Change from baseline over time in Medical Outcome Study Short Form 36 (SF-36) domain scores
SF-36 Domain | Treatment Group | Week 8 | Week 16 | Week 26 | End Point |
|---|---|---|---|---|---|
Physical Functioning | Placebo | 3.2 ± 0.8 | 3.2 ± 0.9 | 5.0 ± 1.0 | 3.6 ± 0.9 |
Topiramate | 4.8 ± 0.8 | 6.4 ± 0.9 | 8.3 ± 1.0 | 5.3 ± 0.8 | |
NS | p = 0.025 | p = 0.023 | NS | ||
Bodily Pain | Placebo | 6.2 ± 1.2 | 6.7 ± 1.3 | 6.7 ± 1.4 | 4.6 ± 1.2 |
Topiramate | 12.0 ± 1.1 | 14.3 ± 1.4 | 14.5 ± 1.4 | 11.5 ± 1.2 | |
p < 0.001 | p < 0.001 | p < 0.001 | p < 0.001 | ||
Vitality | Placebo | 1.9 ± 1.0 | 3.1 ± 1.0 | 3.9 ± 1.2 | 1.8 ± 1.0 |
Topiramate | 3.8 ± 1.0 | 7.9 ± 1.1 | 10.1 ± 1.2 | 5.2 ± 1.0 | |
NS | p = 0.008 | p < 0.001 | p = 0.035 | ||
General Health | Placebo | 1.0 ± 0.7 | 0.4 ± 0.8 | 1.6 ± 0.9 | 0.8 ± 0.8 |
Topiramate | 3.4 ± 0.7 | 4.3 ± 0.9 | 4.5 ± 0.9 | 2.2 ± 0.8 | |
p = 0.009 | p < 0.001 | p = 0.027 | NS | ||
Role- Emotional | Placebo | 4.5 ± 2.0 | 4.1 ± 2.1 | 6.5 ± 2.3 | 3.0 ± 2.0 |
Topiramate | 2.2 ± 2.0 | 8.0 ± 2.2 | 9.3 ± 2.3 | 2.3 ± 2.0 | |
NS | NS | NS | NS | ||
Role- Physical | Placebo | 14.4 ± 2.2 | 15.0 ± 2.2 | 15.9 ± 2.5 | 12.0 ± 2.1 |
Topiramate | 19.3 ± 2.2 | 26.6 ± 2.4 | 24.1 ± 2.5 | 17.9 ± 2.1 | |
NS | p < 0.001 | p = 0.018 | NS | ||
Mental Health | Placebo | -0.2 ± 0.9 | 0.8 ± 0.8 | 0.6 ± 1.0 | -0.2 ± 0.9 |
Topiramate | -1.5 ± 0.9 | 2.9 ± 0.9 | 3.2 ± 1.0 | -0.5 ± 0.9 | |
NS | NS | p = 0.034 | NS | ||
Social Functioning | Placebo | 5.3 ± 1.2 | 7.8 ± 1.2 | 6.8 ± 1.3 | 4.8 ± 1.2 |
Topiramate | 4.8 ± 1.2 | 8.5 ± 1.3 | 10.8 ± 1.3 | 4.8 ± 1.2 | |
NS | NS | p = 0.010 | NS | ||
Physical Component Summary | Placebo | 2.8 ± 0.4 | 2.8 ± 0.4 | 3.2 ± 0.5 | 2.5 ± 0.4 |
Topiramate | 5.1 ± 0.4 | 5.7 ± 0.5 | 5.7 ± 0.5 | 4.7 ± 0.4 | |
p < 0.001 | p < 0.001 | p < 0.001 | p < 0.001 | ||
Mental Component Summary | Placebo | 0.3 ± 0.6 | 0.8 ± 0.5 | 0.9 ± 0.6 | 0.1 ± 0.5 |
Topiramate | -0.6 ± 0.6 | 1.5 ± 0.6 | 2.2 ± 0.6 | -0.2 ± 0.5 | |
NS | NS | p = 0.043 | NS |